CERo Therapeutics Holdings, Inc. (CERO) Doses First Patient in CER-1236 CAR-T AML Trial

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) has achieved a major milestone in the fight against acute myeloid leukemia (AML), announcing today the successful dosing of the first patient in its pioneering Phase 1 trial of CER-1236, an innovative autologous CAR-T cell therapy targeting TIM-4-L. The milestone marks a crucial step forward for a therapy that harnesses engineered T cells with phagocytic capabilities, offering new hope for patients with relapsed/refractory AML, those in remission with measurable residual disease, and newly diagnosed patients with TP53-mutated MDS/AML or AML.

CERo Therapeutics Holdings, Inc. (CERO) Doses First Patient in Phase 1 Trial of Novel CAR-T Therapy CER-1236 for AML

A scientist at a state-of-the-art laboratory closely examining a cellular therapy sample.

The open-label, multi-center study, led by Dr. Abhishek Maiti of MD Anderson Cancer Center, is now underway with intensive safety, efficacy, and pharmacokinetic monitoring. The trial is designed in two parts—dose escalation to identify the optimal dose, followed by an expansion phase to further assess safety and effectiveness. Primary measures include adverse event rates, dose-limiting toxicities, and overall response rates, with secondary endpoints tracking pharmacokinetics.

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO)’s Chief Medical Officer, Dr. Robert Sikorski, highlighted the significance of this first-in-human dosing, noting ongoing protocol-driven evaluations and anticipation for forthcoming data. The company will present a detailed poster at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting in Chicago, where Dr. Sikorski will be available to discuss the trial protocol and early insights.

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) CEO Chris Ehrlich expressed gratitude to all involved and optimism for the potential of CER-1236 to validate groundbreaking scientific advances in cellular immunotherapy. The poster session, titled “Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes and Allotransplant,” is scheduled for June 1 at McCormick Place Convention Center.

While we acknowledge the potential of CERO to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CERO and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Cancer Stocks to Invest in for Long-Term Gains and 10 Most Oversold Stocks to Buy According to Billionaires.

Disclosure: None.